Improvement of atopic dermatitis-like symptoms in a murine model via the chromogranin A-derived peptide catestatin

Collectively, these findings suggest CST as a promising therapeutic agent for AD, capable of enhancing skin barrier function, modulating immune responses, and targeting the Notch1/PKC pathway, offering a novel approach to AD treatment focusing on barrier restoration and immune modulation.